Afficher la couverture 'Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant | Jullien, Maxime' en grand format
/5

0 avis

Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant

Archive ouverte

Jullien, Maxime | Coste‐burel, Marianne | Clemenceau, Beatrice | Letailleur, Valentin | Guillaume, Thierry | Peterlin, Pierre | Garnier, Alice | Bourgeois, Amandine, Le | Imbert, Berthe‐marie | Ollier, Jocelyn | Grain, Audrey | Touzeau, Cyrille | Moreau, Philippe | Béné, Marie, C | Vié, Henri | Chevallier, Patrice

Edité par CCSD ; Wiley -

International audience. The impact of pre-transplant anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in 20 recipients of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and/or their donors is reported here, showing that the persistence of anti-SARS-CoV-2 antibodies can be detected in almost all patients, whatever the type of vaccine used, and up to 9 months post transplant. Also, an anti-SARS-CoV-2 spike glycoprotein CD3+ T-cell response could be detected in six (35%) of 17 evaluable patients. This study provides a rationale to consider anti-SARS-CoV-2 vaccination of both recipients and donors before Allo-HSCT.

Suggestions

Du même auteur

Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy

Archive ouverte | Gastinne, Thomas | CCSD

International audience. No abstract available

Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant

Archive ouverte | Le Bourgeois, Amandine | CCSD

International audience. No abstract available

Efficacy of anti‐severe acute respiratory syndrome coronavirus 2 mRNA vaccines in adults with severe acquired aplastic anemia with or without allogeneic hematopoietic stem cell transplantation

Archive ouverte | Garnier, Alice | CCSD

International audience. No abstract available

Chargement des enrichissements...